|
Clinical Research Studies
Southern Vitreoretinal Associates has an established history of conducting and developing clinical research protocols in the treatment of vitreoretinal diseases and disorders. We work in partnership with study volunteers, study sponsors, and the FDA toward the development of improved treatments for vitreoretinal issues. Southern Vitreoretinal Associates is committed to
conducting accurate and timely clinical trials with an emphasis on bringing the latest research developments to our region.
Southern Vitreoretinal Associates offer patients the opportunity to participate in clinical trials conducted at our facility. Experimental therapy for select conditions is available, and may be a valuable alternative to traditional treatments. By participating in a clinical trial, patients help to further increase medical technology. Clinical trials turn biomedical research into state-of-the-art health care. Through the research collected in the clinical trials, new and/or better treatments can be made available to patients with a particular condition.
Our experienced clinical study coordinator works closely with patients and our physicians on a variety of clinical trials. Our physicians are involved as primary or sub-investigators in ongoing research projects. If you are interested in being considered for a research project, please advise your physician.
|
Sponsor |
Indication |
Criteria |
Drug |
Delivery |
Length |
Genentech
(HORIZON)
Phase III
|
CNV subjects previously treated with rhuFab
|
Genentech
(HORIZON)
Phase III
|
rhuFab V2
Ranibizumab
(Lucentis)
|
Intravitreal injection |
Up to 24 Months |
Genentech
(SAILOR)
Phase III
|
Choroidal
Neovascular
Membrane
|
Genentech
(SAILOR)
Phase III
|
rhuFab V2
Ranibizumab (Lucentis)
|
Intravitreal injection |
12 months |
|
Macular Edema due to BRVO or CRVO |
Allergan
(Posurdex A)
|
700mg Dexamethasone
vs
350 mg Dexamethasone
(DEX)
vs
sham
|
Injection using Posterior Segment Drug Delivery System Applicator
(DEX PS DDS)
|
12 months
(6 months masked, 6 months open-label)
|
|
Diabetic Macular Edema |
|
700mg Dexamethasone
vs
350 mg Dexamethasone
(DEX)
vs
sham
|
Injection using Posterior Segment Drug Delivery System Applicator
(DEX PS DDS) |
36 months |
|
Creation of a PVD |
Bausch
& Lomb
Phase 1b
|
Plasmin |
Intravitreal injection |
6 months |
|
|
